OneMedNet Accelerates AI Drug Development with Rapid Data Delivery
Event summary
- OneMedNet's iRWD Platform enabled cohort feasibility within minutes, data validation within a week, and contract signing within three weeks for an AI-driven drug development company.
- The platform delivers de-identified, full-fidelity clinical Real-World Data from a network exceeding 90 million patient journeys and 2,300 healthcare partner sites.
- OneMedNet's data spans Radiology, Cardiology, EEG, ECG, and other diagnostic modalities, with optional tokenized linkage for multimodal datasets.
- The agreement highlights the growing demand for private healthcare clinical data sourced directly from healthcare providers.
The big picture
OneMedNet's agreement underscores the critical role of high-quality, direct-from-source Real-World Data in AI-driven drug development. The platform's ability to rapidly deliver regulatory decision-grade data positions it as foundational infrastructure for the healthcare and life sciences ecosystem. This deal reflects broader industry trends toward leveraging AI and real-world data to accelerate therapy discovery and development.
What we're watching
- Data Quality
- How OneMedNet's direct-from-source data quality will impact AI model accuracy and regulatory approvals.
- Market Demand
- Whether the surge in demand for private healthcare data can be sustained amid increasing competition.
- Execution Pace
- The pace at which OneMedNet can scale its network and maintain rapid feasibility-to-delivery timelines.
Related topics